IgA nephropathy can be divided into five stages, where stages one to two are relatively mild, early stages, and generally have a good prognosis. For patients with stage two IgA nephropathy, it is rare for the condition to progress to uremia, but whether treatment is needed largely depends on the clinical manifestations of the IgA nephropathy. If a patient with IgA nephropathy has a 24-hour urinary protein quantification greater than 0.5g, it is advisable to use an angiotensin-converting enzyme inhibitor or an angiotensin II receptor antagonist to protect kidney function and reduce urinary protein. If a stage two IgA nephropathy patient only shows microscopic hematuria, drug treatment is not necessary. However, routine urinalysis and kidney function monitoring should be conducted in daily life, and if an infection occurs, timely anti-infection treatment should be administered. If a stage two IgA nephropathy patient has significant proteinuria, steroid treatment is often required. (Medication should be taken under the guidance of a doctor.)